Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
- PMID: 29708118
- PMCID: PMC5906233
- DOI: 10.21037/jtd.2018.03.97
Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Figures
Comment on
-
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
References
-
- NSCLC Meta-analyses Collaborative Group , Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77. 10.1016/S0140-6736(10)60059-1 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous